The phrase "a suitable agent for" is correct and usable in written English.
It can be used when discussing an appropriate representative or substance for a specific purpose or function.
Example: "The research indicates that this compound acts as a suitable agent for enhancing the growth of certain plant species."
Alternatives: "an appropriate agent for" or "a fitting agent for".
Hence this subunit could be used as a suitable agent for antibody antigen based diagnostic test.
The study was conducted to investigate the inhibitory effect of 4- 2-aminoethyl benzenesulfonyl fluoride hydrochloride (AEBSF) on embryo implantation in mice with a view to identifying whether it might be a suitable agent for postcoital contraception.
An ammonium-nitrate-urea solution that is used as a fertilizer in agriculture was found to be a suitable agent for long-term foam suppression for sugar beet co-digestion in practice.
It is well known that oral administration of GSH does not result in its effective increase in the brain because of its poor penetration through the blood-brain barrier, indicating that GSH is not a suitable agent for treating neuropsychiatric diseases such as schizophrenia.
However, TDG, is a suitable agent for blocking the protective functions of galectin-1 on ECs.
Myelosuppression was rare, making capecitabine a suitable agent for pretreated patients.
This finding alerts that the commercial TMPyP4 tetratosylate may not be a suitable agent used for TMPyP4's bioassays related to G-quadruplex stabilization [ 12– 19], and proposed the usage of TMPyP4 tetrachloride as a better one for G-quadruplex research.
Its superior efficacy in advanced disease, together with its improved tolerability and convenient dosage, make it a suitable agent to be assessed for the treatment of early breast cancer in postmenopausal women.
Since [18F]FE@SNAP uptake was significantly blocked in the lateral hypothalamus, there is strong evidence that [18F]FE@SNAP is a highly suitable agent for specific MCHR1 imaging in the central nervous system.
LLL-3, a structural analogue of STA-21 with a smaller molecular weight and the added benefit of being easier to synthesise, may be a more suitable agent for targeting cancer cells with constitutively activated STAT3 pathway.
Although the rarity of infant ALL precludes investigation of every suitable drug, the use of adaptive 'pick a winner' trial designs or assessment of novel agents within the relapsed/refractory disease setting may enable differentiation of the most suitable agent for further investigation.
